Janux Therapeutics (NASDAQ:JANX) and Zai Lab (NASDAQ:ZLAB) Head-To-Head SurveyDefense World · Oct 13, 2026
Head-To-Head Review: Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)Defense World · Oct 6, 2026
4 Prostate Cancer Drug Stocks to Watch During Awareness MonthZacks Investment Research · Sep 15, 2026
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013Business Wire · Sep 14, 2026
Here Are Monday’s Top Wall Street Analyst Research Calls: AstraZeneca, Celestica, Chipotle Mexican Grill, Domino’s Pizza, Fortune Brands, Golar LNG, Jersey Mike’s Subs, Roku, and More247 Wallst · Aug 24, 2026
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to KnowZacks Investment Research · Aug 21, 2026Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.25 | -$0.35 | Miss |
| May 7, 2026 | -$0.52 | -$0.39 | Beat |
| Feb 26, 2026 | -$0.65 | -$0.51 | Beat |
| Nov 6, 2025 | -$0.60 | -$0.39 | Beat |
| Aug 7, 2025 | -$0.48 | -$0.55 | Miss |
| May 8, 2025 | -$0.43 | -$0.38 | Beat |